Take on RMS Challenges
With Dramatic Results

In 2 studies vs AUBAGIO® (teriflunomide), KESIMPTA® was proven superior at reducing the rate of relapses and active lesions, and slowing disability progression.*

Important Safety Information

Who should not take KESIMPTA? Do NOT take KESIMPTA if you have active hepatitis B virus (HBV) infection.

What is the most important information I should know about KESIMPTA? KESIMPTA can cause serious ...

See More

What is KESIMPTA (ofatumumab) injection? KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease.

It is not known if KESI...

See More

MS=multiple sclerosis; RMS=relapsing multiple sclerosis.

*AUBAGIO (teriflunomide), an oral relapsing MS treatment, is a registered trademark of Sanofi and Genzyme.
Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance coverage for KESIMPTA may receive up to $18,000 in annual copay benefits. Patients with commercial insurance and an initial denial of coverage may receive up to 12 months of free product while coverage is pursued. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions at start.kesimpta.com.

5/21 122419